SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Total Assets · Q3 FY2026 · quarter ended Sep 2026
Total assets rises 173.7% from a year ago
Total assets stood at $141.09M at the end of Q3 FY2026, up 173.7% from a year earlier and down 3.0% from the prior quarter. Over 3 fiscal years it compounded at +55.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +173.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 78.35M USD
- Year-over-year change
- +303.2%
- 4-year CAGR
- +31.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.35M | +303.2% |
| FY2024 | 2024-12-31 | 19.43M | +212.5% |
| FY2023 | 2023-12-31 | 6.22M | -70.3% |
| FY2022 | 2022-12-31 | 20.94M | -20.8% |
| FY2021 | 2021-12-31 | 26.43M | — |
Total Assets vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +173.7% is the 2nd highest of 11, against a peer median of +43.4%.
- Over three fiscal years its annual growth of +55.2% compares with a peer median of +15.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $7.87B USD | +35.2% | +6.0% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥3.97B CNY | +51.5% | +11.9% |
| Aug 2026 | $1.2B USD | +128.8% | +18.2% | |
| Mar 2026 | $1.03B USD | -6.4% | +41.9% | |
| Sep 2026 | $505.53M USD | +68.9% | +205.1% | |
| Mar 2026 | $349.3M USD | +62.1% | +22.1% | |
| Mar 2026 | $328.86M USD | +2.9% | -5.9% | |
| Mar 2026 | $217.87M USD | -3.0% | -3.9% | |
| Mar 2026 | $199.13M USD | +3223.2% | +66.8% | |
| Sep 2026 | $141.09M USD | +173.7% | +55.2% | |
| Mar 2026 | $119.64M USD | -15.3% | -13.8% | |
| Peer median (excluding SLS) | — | +43.4% | +15.0% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.46M | 17.13M | 2.53M | 13.89M | 71.89M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 27K | 330K | 100K | 100K | 223K |
| Total Current Assets | 23.04M | 17.76M | 3.17M | 16.33M | 75.21M |
| Property, Plant & Equipment (Net) | 723K | 874K | 858K | 925K | 963K |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | (184K) | 0 | 0 | 0 |
| Tax Assets | 152K | 184K | 0 | 0 | 0 |
| Other Non-current Assets | 594K | 399K | 275K | 466K | 257K |
| Total Non-current Assets | 3.38M | 3.19M | 3.05M | 3.31M | 3.13M |
| Total Assets | 26.43M | 20.94M | 6.22M | 19.43M | 78.35M |
| Account Payables | 2.14M | 3.36M | 5.64M | 3.5M | 2.95M |
| Short-term Debt | 198K | 0 | 0 | 0 | 544K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.65M | 5.5M | 1.54M | 1.82M | 1.77M |
| Total Current Liabilities | 4.98M | 15.52M | 13.74M | 9.51M | 7.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 152K | 184K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | (184K) | 0 | 0 | 0 |
| Other Non-current Liabilities | 336K | 4K | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.1M | 577K | 460K | 457K | 457K |
| Total Liabilities | 6.08M | 16.09M | 14.2M | 9.97M | 7.47M |
| Common Stock | 2K | 2K | 3K | 7K | 15K |
| Retained Earnings | (138.6M) | (179.9M) | (217.24M) | (248.13M) | (274.99M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 20.35M | 4.85M | (7.98M) | 9.47M | 70.87M |
| Total Debt | 808K | 945K | 906K | 1M | 1M |
| Net Debt | (20.65M) | (16.18M) | (1.62M) | (12.89M) | (70.89M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.